Saravana M. Dhanasekaran
University of Michigan
129 Papers
454 Citations
Saravana M. Dhanasekaran is an academic researcher from University of Michigan. The author has contributed to research in topics: Prostate cancer & Biology. The author has an hindex of 50, co-authored 94 publications. Previous affiliations of Saravana M. Dhanasekaran include Kalasalingam University.
Chat about Author
Papers
The landscape of antisense gene expression in human cancers
O. Alejandro Balbin,Rohit Malik,Saravana M. Dhanasekaran,John R. Prensner,Xuhong Cao,Yi-Mi Wu,Dan R. Robinson,Rui Wang,Guoan Chen,David G. Beer,Alexey I. Nesvizhskii,Arul M. Chinnaiyan +11 more
TL;DR: Overall, this study provides a comprehensive account of NATs and supports a role for NATs' regulation of tumor suppressors and oncogenes in cancer biology.
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer
Bo Han,Rohit Mehra,Saravana M. Dhanasekaran,Jindan Yu,Anjana Menon,Robert J. Lonigro,Xiaosong Wang,Yusong Gong,Lei Wang,Sunita Shankar,Bharathi Laxman,Rajal B. Shah,Sooryanarayana Varambally,Nallasivam Palanisamy,Scott A. Tomlins,Chandan Kumar-Sinha,Arul M. Chinnaiyan +16 more
TL;DR: By screening the entire ETS transcription factor family for rearrangements, it is found that a large fraction of prostate cancers cannot be ascribed to an ETS gene fusion, an observation which will stimulate research into identifying recurrent non-ETS aberrations in prostate cancers.
169
Integrative analysis of genomic aberrations associated with prostate cancer progression
Jung H. Kim,Saravana M. Dhanasekaran,Rohit Mehra,Scott A. Tomlins,Wenjuan Gu,Jianjun Yu,Chandan Kumar-Sinha,Xuhong Cao,Atreya Dash,Lei Wang,Debashis Ghosh,Kerby Shedden,James E. Montie,Mark A. Rubin,Kenneth J. Pienta,Rajal B. Shah,Arul M. Chinnaiyan +16 more
TL;DR: Integrative analysis of genomic aberrations in the context of trancriptomic alterations will lead to a more comprehensive perspective on prostate cancer progression, including precursor lesions, clinically localized disease, and metastatic disease.
150
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
Saravana M. Dhanasekaran,O. Alejandro Balbin,Guoan Chen,Ernest Nadal,Shanker Kalyana-Sundaram,Jincheng Pan,Brendan A. Veeneman,Xuhong Cao,Rohit Malik,Pankaj Vats,Rui Wang,Stephanie Huang,Jinjie Zhong,Xiaojun Jing,Matthew K. Iyer,Yi-Mi Wu,Paul W. Harms,Jules Lin,Rishindra M. Reddy,Christine Brennan,Nallasivam Palanisamy,Andrew C. Chang,Anna Truini,Mauro Truini,Dan R. Robinson,David G. Beer,Arul M. Chinnaiyan +26 more
TL;DR: It is shown that higher numbers of gene fusions is an independent prognostic factor for poor survival in lung cancer and suggests that NRG1, NF1 and Hippo pathway fusions may play important roles in tumors without known driver mutations.
The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.
Rohit Malik,Lalit Patel,John R. Prensner,Yang Shi,Matthew K. Iyer,Shruthi Subramaniyan,Alexander Carley,Yashar S. Niknafs,Anirban Sahu,Sumin Han,Teng Ma,Meilan Liu,Irfan A. Asangani,Xiaojun Jing,Xuhong Cao,Saravana M. Dhanasekaran,Dan R. Robinson,Felix Y. Feng,Arul M. Chinnaiyan +18 more
TL;DR: This study identifies PCAT29 as the first androgen receptor–repressed lncRNA that functions as a tumor suppressor in prostate cancer and that its loss may identify a subset of patients at higher risk for disease recurrence.
141